307 related articles for article (PubMed ID: 33792650)
1. Radioiodine Remnant Ablation for Differentiated Thyroid Cancer: A Systematic Review and Meta-analysis.
James DL; Ryan ÉJ; Davey MG; Quinn AJ; Heath DP; Garry SJ; Boland MR; Young O; Lowery AJ; Kerin MJ
JAMA Otolaryngol Head Neck Surg; 2021 Jun; 147(6):544-552. PubMed ID: 33792650
[TBL] [Abstract][Full Text] [Related]
2. Ablation rate after radioactive iodine therapy in patients with differentiated thyroid cancer at intermediate or high risk of recurrence: a systematic review and a meta-analysis.
Klain M; Nappi C; Zampella E; Cantoni V; Green R; Piscopo L; Volpe F; Manganelli M; Caiazzo E; Petretta M; Schlumberger M; Cuocolo A
Eur J Nucl Med Mol Imaging; 2021 Dec; 48(13):4437-4444. PubMed ID: 34142215
[TBL] [Abstract][Full Text] [Related]
3. Applying postoperative radioiodine therapy before 3 months seems to decrease ablation success in patients with differentiated thyroid carcinoma.
Özdoğan Ö; Aksu A; Doğan E; Bülbül O; Güray Durak M; Sevinç Aİ; Bayraktar F; İkiz AÖ
Ann Nucl Med; 2021 Feb; 35(2):223-231. PubMed ID: 33389664
[TBL] [Abstract][Full Text] [Related]
4. Radioiodine versus no radioiodine outcomes in low-risk differentiated thyroid cancers: A propensity-score matched analysis.
Satapathy S; Tupalli A; Chandekar KR; Ballal S; Bal C
Clin Endocrinol (Oxf); 2023 Nov; 99(5):483-491. PubMed ID: 37491776
[TBL] [Abstract][Full Text] [Related]
5. The Effectiveness of Radioactive Iodine Remnant Ablation for Papillary Thyroid Microcarcinoma: A Systematic Review and Meta-analysis.
Hu G; Zhu W; Yang W; Wang H; Shen L; Zhang H
World J Surg; 2016 Jan; 40(1):100-9. PubMed ID: 26578322
[TBL] [Abstract][Full Text] [Related]
6. Comparison between the different doses of radioactive iodine ablation prescribed in patients with intermediate-to-high-risk differentiated thyroid cancer.
Iizuka Y; Katagiri T; Ogura K; Mizowaki T
Ann Nucl Med; 2019 Jul; 33(7):495-501. PubMed ID: 30955202
[TBL] [Abstract][Full Text] [Related]
7. Post-surgical thyroid ablation with low or high radioiodine activities results in similar outcomes in intermediate risk differentiated thyroid cancer patients.
Castagna MG; Cevenini G; Theodoropoulou A; Maino F; Memmo S; Claudia C; Belardini V; Brianzoni E; Pacini F
Eur J Endocrinol; 2013 Jul; 169(1):23-9. PubMed ID: 23594687
[TBL] [Abstract][Full Text] [Related]
8. Effects of low-dose and high-dose postoperative radioiodine therapy on the clinical outcome in patients with small differentiated thyroid cancer having microscopic extrathyroidal extension.
Han JM; Kim WG; Kim TY; Jeon MJ; Ryu JS; Song DE; Hong SJ; Shong YK; Kim WB
Thyroid; 2014 May; 24(5):820-5. PubMed ID: 24328997
[TBL] [Abstract][Full Text] [Related]
9. Outcomes after radioiodine ablation in patients with thyroid cancer: Long-term follow-up of a Chinese randomized clinicaltrial.
Dong P; Qu Y; Yang L; Xiao L; Huang R; Li L
Clin Endocrinol (Oxf); 2021 Nov; 95(5):782-789. PubMed ID: 34368999
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of low radioiodine activity versus intermediate-high activity in the ablation of low-risk differentiated thyroid cancer.
Albano D; Bonacina M; Durmo R; Bertagna F; Giubbini R
Endocrine; 2020 Apr; 68(1):124-131. PubMed ID: 31784881
[TBL] [Abstract][Full Text] [Related]
11. Age, thyroglobulin levels and ATA risk stratification predict 10-year survival rate of differentiated thyroid cancer patients.
Kelly A; Barres B; Kwiatkowski F; Batisse-Lignier M; Aubert B; Valla C; Somda F; Cachin F; Tauveron I; Maqdasy S
PLoS One; 2019; 14(8):e0221298. PubMed ID: 31425569
[TBL] [Abstract][Full Text] [Related]
12. The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: a systematic analysis of the peer-reviewed literature from 1966 to April 2008.
Sacks W; Fung CH; Chang JT; Waxman A; Braunstein GD
Thyroid; 2010 Nov; 20(11):1235-45. PubMed ID: 21062195
[TBL] [Abstract][Full Text] [Related]
13. Radioiodine remnant ablation in papillary thyroid microcarcinoma: a meta-analysis.
Yang T; Zheng SY; Jiao J; Zou Q; Zhang Y
Nucl Med Commun; 2019 Jul; 40(7):711-719. PubMed ID: 31095043
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of adjuvant radioactive iodine after reoperation in patients with persistent or recurrent differentiated thyroid cancer: a systematic review.
Raghupathy J; Tan BKJ; Song HJJMD; Chia AZQ; Tan YZ; Yang SP; Parameswaran R
Langenbecks Arch Surg; 2023 Jan; 408(1):21. PubMed ID: 36635455
[TBL] [Abstract][Full Text] [Related]
15. Intermediate-risk differentiated thyroid carcinoma patients who were surgically ablated do not need adjuvant radioiodine therapy: long-term outcome study.
Ballal S; Soundararajan R; Garg A; Chopra S; Bal C
Clin Endocrinol (Oxf); 2016 Mar; 84(3):408-16. PubMed ID: 25823589
[TBL] [Abstract][Full Text] [Related]
16. Serum thyroglobulin level after radioiodine therapy (Day 3) to predict successful ablation of thyroid remnant in postoperative thyroid cancer.
Kim YI; Im HJ; Paeng JC; Cheon GJ; Kang KW; Lee DS; Joon Park D; Park YJ; Chung JK
Ann Nucl Med; 2015 Feb; 29(2):184-9. PubMed ID: 25404419
[TBL] [Abstract][Full Text] [Related]
17. Referral Practice for Radioactive Iodine Ablation (RAI) after ATA guidelines 2015: results from a Tertiary Cancer Care Centre.
Dhar H; Thiagarajan S; Yousuf A; Nayyar SS; Chaukar D
Eur Arch Otorhinolaryngol; 2020 Sep; 277(9):2521-2526. PubMed ID: 32240364
[TBL] [Abstract][Full Text] [Related]
18. rhTSH-aided low-activity versus high-activity regimens of radioiodine in residual ablation for differentiated thyroid cancer: a meta-analysis.
Ma C; Tang L; Fu H; Li J; Wang H
Nucl Med Commun; 2013 Dec; 34(12):1150-6. PubMed ID: 24025918
[TBL] [Abstract][Full Text] [Related]
19. Longer-term recurrence rate after low versus high dose radioiodine ablation for differentiated thyroid Cancer in low and intermediate risk patients: a meta-analysis.
Vardarli I; Weidemann F; Aboukoura M; Herrmann K; Binse I; Görges R
BMC Cancer; 2020 Jun; 20(1):550. PubMed ID: 32539683
[TBL] [Abstract][Full Text] [Related]
20. Radioactive Iodine Ablation Can Reduce the Structural Recurrence Rate of Intermediate-Risk Papillary Thyroid Microcarcinoma: A Meta-Analysis.
Zhao M; Shi X; Zhang J; Deng S; Zhou Y; Wen R; Lu Y; Zhang B
Comput Math Methods Med; 2022; 2022():8028846. PubMed ID: 36110571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
